Market Watch: the FDA declined to exempt radiology AI from 510(k)

What changed. On 17 September 2026 the FDA published its denial of a petition seeking partial exemption from premarket notification for radiology computer-aided detection and diagnosis devices.¹

The petition, filed on 22 October 2025, covered four generic device types across six product codes: POK, MYN, QAS, QFM, QBS and QDQ. The FDA found that it "does not demonstrate that premarket notification is not necessary" to provide reasonable assurance of safety and effectiveness.¹

Note the direction, because it has been reported the wrong way round. This is a refusal, not a grant. Several trackers have recorded it as an exemption being created. It is the opposite.

Why it matters. Imaging AI stays on the 510(k) path in the United States. A number of entrants were planning around the shortcut this petition sought, and building a regulatory timeline on an exemption that has now been formally refused is an expensive assumption to carry.

The broader signal is about direction rather than this one decision. The FDA was asked whether a category of AI-enabled devices had matured enough that premarket review no longer added assurance, and said no. For anyone sequencing a digital health or SaMD launch, that answer travels well beyond radiology.

What to do now. If your US plan assumed a Class II exemption for a computer aided detection or diagnosis product, check your product code against the six in the petition and rebuild the timeline around a 510(k).

Then look at where the boundary is actually moving, which is not the United States. Australia replaces its definition of clinical decision support system software on 1 November 2026, and the new conditions turn on whether software is intended to replace the clinical judgement of a health professional.² That changes whether a product needs inclusion in the Australian register at all, which is a more consequential question than exemption from a notification.

Two regulators, two months apart, both redrawing the line around the same class of product. Neither answer transfers to the other market.